The new generation of the RIDA®GENE multiplex real-time PCR kits offers a number of improvements—and makes molecular laboratory diagnostics even more efficient and flexible.
we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal https://eifu.r-biopharm.com.
In February 2020, R-Biopharm was one of the first diagnostics companies worldwide to launch a test kit for the novel coronavirus SARS-CoV-2. Now, the test has received the CE label and is thus [...]
Community-acquired pneumonia (CAP) is the most common fatal infectious disease in western countries. Bacteria are the most common pathogens causing CAP, where one differentiates between typical [...]
The COVID-19 infection figures continue to rise and with them the fear: How long can regular school operations be maintained? Experts warn of renewed school closings and recommend specific measures.
The RIDA®GENE real-time PCR assays (RIDA®GENE Flu, RIDA®GENE Flu LC2.0, RIDA®GENE Flu & RSV) successfully detected the suggested vaccination strains for influenca of the 2015/2016 season.
RIDA®GENE Enterovirus – the new real-time RT-PCR assay for the detection of the major human enteroviruses